Table 3 Surgical Outcomes of the Three Study Cohorts with Case-Matched
None (n = 54) | Anti-TNF (n = 74) | Vedolizumab (n = 25) | p | |
|---|---|---|---|---|
Overall morbidity | 20 (37) | 33 (45) | 11 (44) | 0.67 |
Infectious complications | 11 (20) | 8 (11) | 2 (8) | 0.20 |
Pelvic abscess | 0 | 2 (3) | 1 (4) | |
Wound infection | 9 (17) | 5 (8) | 1 (4) | |
Urinary tract | 1 (2) | 0 | 0 | |
Pneumonia | 1 (2) | 0 | 0 | |
Post-operative Ileus | ||||
Grade I | 5 (9) | 12 (16) | 9 (36) | 0.01 |
Grade II | 3(6) | 4(5) | 2(8) | 0.89 |
Other morbidity | 4 (8) | 13 (18) | 1(4) | 0.14 |
Postoperative stay (d) | 6 (5–8) | 6 (5–8) | 5 (3–9) | 0.17 |
30-day readmission | 7 (13) | 11 (15) | 1 (4) | 0.36 |